Manage Tickers

Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current
Analyst Rating Guide

News

Back

Arcturus Therapeutics Q2 2024 GAAP EPS $(0.64) Beats $(1.62) Estimate, Sales $49.859M Beat $21.696M Estimate

Author: Benzinga Newsdesk | August 05, 2024 04:05pm
Arcturus Therapeutics (NASDAQ:ARCT) reported quarterly losses of $(0.64) per share which beat the analyst consensus estimate of $(1.62) by 60.49 percent. The company reported quarterly sales of $49.859 million which beat the analyst consensus estimate of $21.696 million by 129.81 percent. This is a 373.99 percent increase over sales of $10.519 million the same period last year.

Posted In: ARCT


CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist